X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RSLV-132 is a safe, novel, targeted biologic drug designed to remove pro-inflammatory nucleic acids from the circulation of patients, which is one of the key triggers of multiple pro-inflammatory cascades.
Lead Product(s): RSLV-132
Therapeutic Area: Infections and Infectious Diseases Product Name: RSLV-132
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
Based on previous positive phase 2 clinical trial with RSLV-132 in autoimmune fatigue, removing circulating RNA in long covid patients will have a similar improvement in their fatigue and brain fog.
Lead Product(s): RSLV-132
Therapeutic Area: Infections and Infectious Diseases Product Name: RSLV-132
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
The Phase 2 study demonstrated a clinically meaningful improvement in four separate, independent, validated measures of fatigue in the RSLV-132 group, but not the placebo group.
Lead Product(s): RSLV-132
Therapeutic Area: Immunology Product Name: RSLV-132
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
